Homozygous Familial Hypercholesterolemia Is a Life-Limiting Condition: Medical Life-Trajectories in the Post-2010 Era
Status In-Process Language English Country United States Media print
Document type Journal Article
Grant support
P01 HL059407
NHLBI NIH HHS - United States
PubMed
40368578
PubMed Central
PMC12088375
DOI
10.1016/j.jacc.2025.04.005
PII: S0735-1097(25)06167-4
Knihovny.cz E-resources
- Keywords
- ASCVD, LDL-cholesterol, cardiovascular disease, homozygous familial hypercholesterolemia, mortality,
- Publication type
- Journal Article MeSH
Cardiovascular Center Osaka Medical and Pharmaceutical University Takatsuki Japan
Department of Cardiology Hanoi Medical University Hanoi Vietnam
Directorate of Research Shifa Tameer e Millat University Islamabad Pakistan
Ege University Medical Faculty Department of Cardiology Bornova Izmir Turkey
Faculty of Medicine Phenikaa University and Vietnam Atherosclerosis Society Hanoi City Vietnam
See more in PubMed
Cuchel M, Raal FJ, Hegele RA et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J 2023. PubMed PMC
Tromp TR, Hartgers ML, Hovingh GK et al. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet 2022;399:719–728. PubMed PMC
Bruckert E, Kalmykova O, Bittar R et al. Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France. Atherosclerosis 2017;257:130–137. PubMed
Thompson GR, Blom DJ, Marais AD, Seed M, Pilcher GJ, Raal FJ. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J 2018;39:1162–1168. PubMed
Berberich AJ, Hegele RA. The complex molecular genetics of familial hypercholesterolaemia. Nat Rev Cardiol 2019;16:9–20. PubMed
Sturm AC, Knowles JW, Gidding SS et al. Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. J Am Coll Cardiol 2018;72:662–680. PubMed
Mulder J, Tromp TR, Al-Khnifsawi M et al. Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia. JAMA Cardiol 2024. PubMed PMC
Kramer AI, Akioyamen LE, Lee S et al. Major adverse cardiovascular events in homozygous familial hypercholesterolaemia: a systematic review and meta-analysis. Eur J Prev Cardiol 2022;29:817–828. PubMed
Gu J, Kuznik A, Quon P, Chauhan A, Sravya TS, Raal FJ. Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia. Eur J Prev Cardiol 2023;30:1874–1880. PubMed
Leipold R, Raal F, Ishak J, Hovingh K, Phillips H. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Eur J Prev Cardiol 2017;24:1843–1850. PubMed